Initial viral response is the most powerful predictor of the emergence of YMDD mutant virus in chronic hepatitis B patients treated with lamivudine

Authors:

Abstract
Aim:  Lamivudine (LAM) has been widely used to treat chronic hepatitis B (CHB) patients, but the emergence of a LAM‐resistant virus greatly limits its therapeutic efficacy. In this study, we tried to identify factors affecting the emergence of a LAM‐resistant virus in CHB patients treated with LAM.Methods:  The subjects were 190 CHB patients in continuous LAM therapy (139 males, mean age 50 years, 87 HBeAg‐positive). The mean duration of follow‐up was 39 months (range 12–104). The initial viral response (IVR) was defined as HBV DNA < 4.0 logcopies/mL, and the initial biochemical response (IBR) as normalization of alanine aminotransferase (ALT) ( 6.5 logcopies/mL (P = 0.0044), HBeAg‐positivity (P = 0.0062), IBR (P = 0.01) and IVR (P < 0.0001). The cumulative emergence rates of LAM‐resistant virus in IVR‐positive and ‐negative patients were 4% and 41% at 1 year, and 41% and 79% at 3 years. In multivariate analysis, only IVR was an independent factor affecting the emergence of LAM‐resistant virus (P < 0.0001).Conclusion:  IVR is a useful factor for predicting the emergence of LAM‐resistant virus in CHB patients treated with LAM. For IVR‐negative patients, therapeutic options other than LAM monotherapy should be used because of the high incidence of the emergence of LAM‐resistant virus.

This publication has 23 references indexed in Scilit: